trialsTrialActive

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A phase 3 trial of Sacituzumab govitecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.

Also called: EVOKE-01

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT05089734 by Gilead Sciences, with 603 participants enrolled, started 2021-11-17 and due to reach its primary completion in 2023-11-29. Interventions recorded: Sacituzumab Govitecan-hziy (SG), Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

Setting

Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Phase

Phase 3

Sponsor

Gilead Sciences

Registry

Started

2021-11-17

Reported

2025

Enrolled

603 enrolled

Outcomes

In plain words

What these results mean for people, not percentages

603 enrolled

Overall Survival (OS)primarysurvival endpoint

Median 11.1 vs 9.8 months with Sacituzumab Govitecan (SG) compared with Docetaxel; about 1.3 months longer for half the group.
A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
Put another way, the treated group had about 16 percent lower chance of the event at any given time (hazard ratio 0.84, likely range 0.68 to 1.04).

The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
These results apply to the people the trial enrolled: Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. People in a different situation may not see the same effect.
The trial selected people by a biomarker (PD-1); the result should not be assumed for people whose cancer does not have it.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

603 enrolled.

Overall Survival (OS)primary

HR 0.84 (0.68 to 1.04) · p = 0.0534

Download

95% CI 9.4 to 12.3; Figures from the ClinicalTrials.gov results section (first posted 2025-01-14), not from a publication · 95% CI 8.1 to 10.6

Endpoint	Arm	n	Value	HR (95% CI)	p	Source
Overall Survival (OS)primary	Sacituzumab Govitecan (SG)	299	11.1 months	0.84 (0.68 to 1.04)	0.0534	link
Overall Survival (OS)primary	Docetaxel	304	9.8 months	0.84 (0.68 to 1.04)	0.0534	link

Connected

Similar pages

cancers

Non-small-cell lung cancer Small-cell lung cancer

technologies

Antibody-drug conjugate (ADC)Cytotoxic chemotherapy Topoisomerase-I inhibitors (and ADC payloads)

drugs

ApprovedCytotoxic chemotherapy (taxane)

Docetaxel · Taxotere (generic)

ApprovedADC

Sacituzumab govitecan · Trodelvy

companies

Gilead Sciences (incl. Kite)